InvestorsHub Logo
Followers 237
Posts 10817
Boards Moderated 0
Alias Born 07/17/2006

Re: None

Wednesday, 03/09/2016 10:51:51 AM

Wednesday, March 09, 2016 10:51:51 AM

Post# of 428931
Putting lipstick on the pig...

For you long suffering Amarites, I promise this will be my last beating of the old grey dead mare.

So what have we gained from these seven long months of hoping and wishing..Certainly not a guarantee the FDA will abide by the agreement. History tells us the FDA is not likely to keep its word...It goes back to the Oct 2013 AdCom-SPA..The ones that got it right (not me) said before the AdComm the FDA would not honor its word and grant the SPA label expansion. They were right. The reality was the the ANCHOR label expansion was just too big for the FDA to grant a 35mil patient target for a drug that had not been tested in the field and proven successful..The FDA knew that long before the AdComm. The conclusion is inescapable that the FDA baited the hook with a phony SPA to get the answer to a very important question.

Investors like myself were just naive thinking the FDA was incapable of such duplicity, not realizing the FDa could easily rationalize their actions on the basis of the greater good to the most people. The FDA is going to act in a manner which it believes supports the greatest good. As far as investors at present, I would say this has never been about personal vendettas or personalities. Realistically the biggest thing Amarin gets out of this "settlement" is that they will have a guardian in terms of the federal judge over viewing the FDa's actions..At present I do not see any major conflicts overhanging the FDA's position and this is very different than how things were in the autumn of 2013. FDA will get its outcomes trial...I am very optimistic about the results...particularly about the secondary endpoints which paradoxically will be more important than the primary endpoint (clinical wise.)

JMHO...":>) JL
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News